Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downg

BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the

To test the hypothesis of the SPY772 program, the company also announced the initiation of SKYLIGHT,

WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Comp

This disposition follows a staggering 500% one-year stock surge.

This sale was executed under a pre-arranged plan as the stock posted a staggering return over 12 mon

Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel

Wells Fargo analyst Yanan Zhu maintains Spyre Therapeutics (NASDAQ:SYRE) with a Overweight and ra

Guggenheim analyst Yatin Suneja maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises

Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform a

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.36) per share which beat the analy

Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE t

Shares of Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) have been given a consensus reco

Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report)'s stock price rose 5.7% during trading on

Goldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers incl

Mizuho analyst Joseph Catanzaro maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and

U.S. stock futures mixed, Nasdaq 100 falls 200 pts. Rivian (RIVN) drops after public offering announ

WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Comp

Spyre Therapeutics is building a long-acting antibody platform across IBD and rheumatology. However,

Spyre Therapeutics  SYRE has given investors a classic biotech dilemma. The pipeline is advancing, t

Spyre Therapeutics  SYRE has become a closely watched clinical-stage biotech stock as investors look

SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but i

Spyre is building a modular immunology platform targeting IBD and rheumatic diseases with internally

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs

Spyre Therapeutics falls 12% amid major insider stock sales. Explore the technical data and market s

U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates

Leifras Co Ltd (NASDAQ: LFS) rose in pre-market trading after acquiring SWIFT JAPAN for JPY454.6 mil

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raise

SAGTEC GLOBAL (NASDAQ: SAGT) gained 75.6% in pre-market trading after projecting 35% revenue growth

Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significa

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to develop

SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p

With AI and space dominating many of the market's most popular investment themes, it can be difficul

Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2

WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Comp

Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating S

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raise

Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELY

Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYW

On May 29, 2026, the Company entered into the First Amendment to Amended and Restated License Agreem

US stock futures lower, Dow futures down 200 points. Norwegian Cruise Line shares fall after Q1 resu

eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, v

Wall Street analysts upgraded several stocks, including Cloudflare, Alector, ProPetro, and Atlas Ene

Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrade

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market